BridgeBio Pharma Profit Margin 2018-2024 | BBIO
Current and historical gross margin, operating margin and net profit margin for BridgeBio Pharma (BBIO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. BridgeBio Pharma net profit margin as of September 30, 2024 is -201.53%.
| BridgeBio Pharma Annual Profit Margins |
| BridgeBio Pharma Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
